Patient Monitoring & Wearables

SHERIDAN, WYOMING – May 5, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval for its Simplera Sync™ sensor, marking a significant expansion of its continuous glucose monitoring (CGM) portfolio in the United States. The approval enables integration of the Simplera Sync™ sensor with the company’s flagship MiniMed™ 780G system, offering greater flexibility and convenience to people managing diabetes through advanced insulin delivery technology.

SHERIDAN, WYOMING – May 5, 2025 – Medtronic plc (NYSE: MDT), a global leader in healthcare technology, has officially submitted 510(k) applications to the U.S. Food and Drug Administration (FDA) for its MiniMed™ 780G pump and SmartGuard™ algorithm, paving the way for seamless integration with Abbott’s advanced continuous glucose monitoring (CGM) platform. This critical regulatory milestone strengthens Medtronic’s strategic partnership with Abbott and positions the company to deliver more interoperable, intelligent diabetes care solutions to the U.S. market.